Mary L Disis

6PUBLICATIONS
58CO-AUTHORS
Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 26, 2025
A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer.

William R Gwin, Lupe G Salazar, James Y Dai

|Jun 09, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.

Mary L Disis, Sarah F Adams, Jyoti Bajpai

|Apr 24, 2023
A Phase I/II Trial of HER2 Vaccine-Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2-Overexpressing Breast Cancer.

Mary L Disis, Yushe Dang, Andrew L Coveler

|Jan 20, 2022
Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report.

Altaf Mohammed, Roderick H Dashwood, Sally Dickinson

|Nov 30, 2021
Breast cancer vaccines for treatment and prevention.

Mary L Disis, Denise L Cecil

|Apr 12, 2021
Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.

Mark Steven Miller, Peter J Allen, Powel H Brown

Pageof 1

Frequent Collaborators

2 joint publications

Mark Steven Miller

2 joint publications

Yushe Dang

2 joint publications

Roderick H Dashwood

2 joint publications

Altaf Mohammed